Genomtec S.A.
Research Genomtec S.A. (GMT) on Bullrun: market cap PLN 54.09M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGMT
- ExchangeWAR
- CountryPoland
- SectorHealthcare
- IndustryMedical Devices
- CurrencyPLN
- Market capPLN 54.09M
- Financial periodQ1 2026
- RevenuePLN 16.00K
- Net income-PLN 2.20M
- Free cash flow-PLN 1.87M
- Gross margin-12531.3%
Valuation Snapshot
latest market cap is PLN 54.09M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-05 | PLN 54.09M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About Genomtec S.A.
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that enables the detection of pathogens, such as viruses, bacteria, and fungi, as well as genetic mutations through the analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Genomtec S.A.'s market cap?
Genomtec S.A.'s market capitalization is PLN 54.09M.
What does Genomtec S.A. do?
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that enables the detection of pathogens, such as viruses, bacteria, and fungi, as well as genetic mutations through the analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detection of viral infectious diseases and other areas.